| Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial MZH Farooqui, J Valdez, S Martyr, G Aue, N Saba, CU Niemann, ... The lancet oncology 16 (2), 169-176, 2015 | 485 | 2015 |
| Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring A Zviran, RC Schulman, M Shah, STK Hill, S Deochand, CC Khamnei, ... Nature medicine 26 (7), 1114-1124, 2020 | 266 | 2020 |
| Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib C Sun, X Tian, YS Lee, S Gunti, A Lipsky, SEM Herman, D Salem, ... Blood, The Journal of the American Society of Hematology 126 (19), 2213-2219, 2015 | 236 | 2015 |
| Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study SEM Herman, CU Niemann, M Farooqui, J Jones, RZ Mustafa, A Lipsky, ... Leukemia 28 (11), 2188-2196, 2014 | 216 | 2014 |
| Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib AH Lipsky, MZH Farooqui, X Tian, S Martyr, AM Cullinane, K Nghiem, ... Haematologica 100 (12), 1571, 2015 | 179 | 2015 |
| Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications Y Herishanu, BZ Katz, A Lipsky, A Wiestner Hematology/Oncology Clinics 27 (2), 173-206, 2013 | 147 | 2013 |
| Managing toxicities of Bruton tyrosine kinase inhibitors A Lipsky, N Lamanna Hematology 2014, the American Society of Hematology Education Program Book …, 2020 | 106 | 2020 |
| Optimizing platelet GPVI inhibition versus haemostatic impairment by the Btk inhibitors ibrutinib, acalabrutinib, ONO/GS-4059, BGB-3111 and evobrutinib V Denzinger, K Busygina, J Jamasbi, I Pekrul, M Spannagl, C Weber, ... Thrombosis and Haemostasis 119 (03), 397-406, 2019 | 35 | 2019 |
| Risk factors for catheter associated urinary tract infections in a pediatric institution NG Lee, D Marchalik, A Lipsky, HG Rushton, HG Pohl, X Song The Journal of urology 195 (4), 1306-1311, 2016 | 34 | 2016 |
| Response to comment on incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib AH Lipsky, JN Lozier, A Wiestner haematologica 101 (3), e124, 2016 | 12 | 2016 |
| Rapid Decrease in Overall Tumor Burden On Ibrutinib (PCI-32765) in CLL Despite Transient Increase in ALC Indicates a Significant Degree of Treatment Induced Cell Death. M Farooqui, G Aue, J Valdez, N Saba, SEM Herman, A Lipsky, ... Blood 120 (21), 2899, 2012 | 12 | 2012 |
| Single agent ibrutinib (PCI-32765) is highly effective in chronic lymphocytic leukaemia patients with 17p deletion A Wiestner, M Farooqui, J Valdez, J Jones, GE Marti, DC Arthur, A Lipsky, ... Hematol Oncol 31 (Suppl 1), 98, 2013 | 9 | 2013 |
| Bendamustine-rituximab in mantle cell lymphoma A Lipsky, P Martin Lancet Haematology, 2016 | 8 | 2016 |
| Asymptomatic enlargement of the clavicle: a review of underlying aetiologies D PEtROv, D MARChALik, A LiPSky, S MiLgRAUM Acta Orthop Belg 76 (6), 715-718, 2010 | 8 | 2010 |
| Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia AH Lipsky, N Lamanna Cancer 129 (1), 18-31, 2023 | 7 | 2023 |
| Targeting CD38 with daratumumab plus chemotherapy for patients with advanced-stage plasmablastoid large B-cell lymphoma YK Ryu, EC Ricker, CR Soderquist, MA Francescone, AH Lipsky, ... Journal of Clinical Medicine 11 (16), 4928, 2022 | 6 | 2022 |
| Dermatologic presentations of orthopedic pathologies: a review of diagnosis and treatment D Marchalik, A Lipsky, D Petrov, JD Harvell, SS Milgraum American journal of clinical dermatology 13, 293-310, 2012 | 6 | 2012 |
| First in human (FIH) study of GFH009, a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with relapsed/refractory (r/r) hematologic malignancies J Qi, K Zhou, W Qian, A Zang, TM Kadia, AH Lipsky, Y Yang, Y Wang, ... Blood 140 (Supplement 1), 9473-9474, 2022 | 5 | 2022 |
| Abstract LB-141: Potent single agent activity of Ibrutinib (PCI-32765) in patients with chronic lymphocytic leukemia (CLL): clinical and translational results from an ongoing … A Wiestner, S Herman, R Mustafa, J Valdez, J Jones, N Saba, A Lipsky, ... Cancer Research 73 (8_Supplement), LB-141-LB-141, 2013 | 5 | 2013 |
| Single-cell multi-omics reveals distinct paths to survival of admixed BTKC481 mutant vs. wild-type cells in clinically progressing chronic lymphocytic leukemia A Lipsky, D Luan, S Chen, R Chaligne, N Dusaj, EB Bhavsar, C Ang, ... Blood 136, 40-42, 2020 | 4 | 2020 |
